TY - JOUR
T1 - The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
AU - Kawamura, M.
AU - Ohara, Shuichi
AU - Koike, T.
AU - Iijima, Katsunori
AU - Suzuki, Jin
AU - Kayaba, S.
AU - Noguchi, Kenji
AU - Hamada, S.
AU - Noguchi, Mitsunori
AU - Shimosegawa, Toru
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Background: The acid suppressive effect of lansoprazole is influenced by the P450 2C19 (CYP2C19) polymorphism. Aim: To investigate whether the CYP2C19 genotype is related to the healing of erosive reflux oesophagitis during treatment with lansoprazole. Methods: Eighty-eight Japanese patients with erosive reflux oesophagitis were treated with a daily oral dose of 30 mg lansoprazole for 8 weeks. The CYP2C19 genotype, Helicobacter pylori infection status and serum pepsinogen I/II ratio were assessed before treatment. At 4 and 8 weeks, the healing of erosive reflux oesophagitis was evaluated endoscopically. Results: The healing rates were 57.1%, 69.2% and 72.7% at 4 weeks and 77.4%, 95.0% and 100% at 8 weeks in homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers, respectively. At 8 weeks, the healing rate of erosive reflux oesophagitis was significantly lower in homozygous extensive metabolizers than in the other two groups (P < 0.05). The H. pylori status and serum pepsinogen I/II ratio had less influence than CYP2C19 polymorphism on the healing rate of erosive reflux oesophagitis. Conclusions: The therapeutic effect of lansoprazole on erosive reflux oesophagitis is influenced by the CYP2C19 genotype status. Therefore, a test of CYP2C19 genotype may be useful for the medical treatment of reflux oesophagitis with lansoprazole.
AB - Background: The acid suppressive effect of lansoprazole is influenced by the P450 2C19 (CYP2C19) polymorphism. Aim: To investigate whether the CYP2C19 genotype is related to the healing of erosive reflux oesophagitis during treatment with lansoprazole. Methods: Eighty-eight Japanese patients with erosive reflux oesophagitis were treated with a daily oral dose of 30 mg lansoprazole for 8 weeks. The CYP2C19 genotype, Helicobacter pylori infection status and serum pepsinogen I/II ratio were assessed before treatment. At 4 and 8 weeks, the healing of erosive reflux oesophagitis was evaluated endoscopically. Results: The healing rates were 57.1%, 69.2% and 72.7% at 4 weeks and 77.4%, 95.0% and 100% at 8 weeks in homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers, respectively. At 8 weeks, the healing rate of erosive reflux oesophagitis was significantly lower in homozygous extensive metabolizers than in the other two groups (P < 0.05). The H. pylori status and serum pepsinogen I/II ratio had less influence than CYP2C19 polymorphism on the healing rate of erosive reflux oesophagitis. Conclusions: The therapeutic effect of lansoprazole on erosive reflux oesophagitis is influenced by the CYP2C19 genotype status. Therefore, a test of CYP2C19 genotype may be useful for the medical treatment of reflux oesophagitis with lansoprazole.
UR - http://www.scopus.com/inward/record.url?scp=0037392311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037392311&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.2003.01539.x
DO - 10.1046/j.1365-2036.2003.01539.x
M3 - Article
C2 - 12656699
AN - SCOPUS:0037392311
VL - 17
SP - 965
EP - 973
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 7
ER -